• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

CMS hesitates to approvePET for cancer despite data

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 1
Volume 31
Issue 1

Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage.

Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage. A CMS advisory panel came to the conclusion that clinical data for nine conditionally approved cancer indications of FDGPET were too ambivalent to support the petition.

The NOPR team suggested that making decisions case by case would be counterproductive. They remain optimistic that CMS will look favorably at the latest findings before making a final coverage decision, which is scheduled for January.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.